Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209592 | 0.87 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8081872 | 0.87 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL26125909 | 0.87 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8243454 | 0.87 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14923517 | 0.86 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13087476 | 0.86 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14151833 | 0.86 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL970179 | 0.86 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL970178 | 0.86 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8234220 | 0.86 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CTSK 4670/4885CTSS 4634/4885CA1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.